PBS listings for BRAF-mutant melanoma and HER-2 positive early breast cancer

PBS access has been widened to include an oral therapy for melanoma patients and adjuvant treatment for women with early breast cancer. From 1 April the targeted oral combination therapy of encorafenib (Braftovi) plus binimetinib (Mektovi) is PBS subsidised to treat adult patients with unresectable Stage III or Stage IV malignant melanoma with a BRAF ...